Memorial Sloan Kettering Cancer Center

The addition of copanlisib to rituximab extended PFS among patients with relapsed follicular lymphoma or marginal zone lymphoma, according to a subset analysis of the randomized phase 3 CHRONOS-3 trial.

Thirty-four physicians have received Fellow of the American Society of Clinical Oncology distinction.

Nearly 40% of patients with advanced or metastatic synovial sarcoma or myxoid/round cell liposarcoma responded to therapy with afamitresgene autoleucel, according to results of a phase 2 study.

An investigational targeted radioligand therapy improved outcomes for certain men with advanced prostate cancer, according to randomized phase 3 study results to be presented during the plenary session of the virtual ASCO Annual Meeting.

The FDA approved piflufolastat F 18 injection, a radioactive diagnostic agent designed to identify suspected metastasis or recurrence of prostate cancer, according to the agent’s manufacturer.

The FDA granted fast track designation to Illuminare-1, a novel nerve visualization agent that locates and delineates nerves during surgery to avoid nerve injury, according to a manufacturer-issued press release.

Memorial Sloan Kettering Cancer Center and the Robbins Family Foundation presented Robbins Family Awards for Nursing Excellence to eight individuals and one team.

Erica Fischer-Cartlidge, DNP, RN, CNS, CBCN, AOCNS, received Oncology Nursing Foundation’s Connie Henke Yarbro Excellence in Cancer Nursing Mentorship Award.

The U.S. Preventive Services Task Force issued updated recommendations for colorectal cancer screening in JAMA.

The combination of daratumumab, carfilzomib, lenalidomide and dexamethasone conferred high rates of minimal residual disease negativity among patients with newly diagnosed multiple myeloma, according to phase 2 study results.